| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3398842 | F | Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay | Western equine encephalitis virus | 22 | ALA3396967 | cell-based format | Scientific Literature | |
| 2. | ALA3398843 | A | Cytotoxicity against human BE(2)-C cells after 18 to 20 hrs by MTT assay | Homo sapiens | 22 | ALA3396967 | cell-based format | Scientific Literature | |
| 3. | ALA3398844 | A | Effective permeability at pH 7.4 by BBB-PAMPA method | 11 | ALA3396967 | assay format | Scientific Literature | ||
| 4. | ALA3398845 | A | Inhibition of human MDR1 expressed in MDCK2 cells assessed as increase of rhodamine 123 uptake at 30 uM up to 240 mins relative to 5 uM tariquidar | Homo sapiens | 11 | ALA3396967 | cell-based format | Scientific Literature | |
| 5. | ALA3398847 | A | Half life in BALB/c mouse liver microsomes at 1 uM in presence of NADPH by HPLC-MS/MS method | Mus musculus | 11 | ALA3396967 | assay format | Scientific Literature | |
| 6. | ALA3398848 | P | Kinetic solubility of the compound in WEEV replication assay medium in presence of 10% fetal bovine serum | 11 | ALA3396967 | small-molecule physicochemical format | Scientific Literature | ||
| 7. | ALA3398849 | F | Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 30.7 +/- 9 x 10'6 pfu/ml) | Fort Morgan virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 8. | ALA3398850 | F | Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral-induced cytopathogenicity by measuring cell viability at 25 uM (Rvb = 35.6 +/- 4.7%) | Fort Morgan virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 9. | ALA3398851 | F | Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 37.3 +/- 7.3 x 10'4 pfu/ml) | Western equine encephalitis virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 10. | ALA3398852 | F | Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 5 uM after 24 hrs by plaque reduction assay (Rvb = 30.7 +/- 9 x 10'6 pfu/ml) | Fort Morgan virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 11. | ALA3398853 | F | Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral-induced cytopathogenicity by measuring cell viability at 5 uM (Rvb = 35.6 +/- 4.7%) | Fort Morgan virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 12. | ALA3398854 | F | Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as reduction of viral titer at 5 uM after 24 hrs by plaque reduction assay (Rvb = 37.3 +/- 7.3 x 10'4 pfu/ml) | Western equine encephalitis virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 13. | ALA3398855 | F | Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay relative to untreated control | Fort Morgan virus | 2 | ALA3396967 | cell-based format | Scientific Literature | |
| 14. | ALA3398856 | F | Antiviral activity against Fort Morgan virus infected in HEK293 cells assessed as reduction of viral titer by plaque reduction assay relative to untreated control | Fort Morgan virus | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 15. | ALA3398857 | F | Antiviral activity against Venezuelan equine encephalitis virus TC-83 vaccine infected in HEK293 cells assessed as reduction of viral titer at 25 uM by plaque reduction assay relative to untreated control | Venezuelan equine encephalitis virus | 2 | ALA3396967 | organism-based format | Scientific Literature | |
| 16. | ALA3398858 | F | Antiviral activity against California encephalitis virus infected in HEK293 cells assessed as reduction of viral titer at 25 uM by plaque reduction assay relative to untreated control | California encephalitis virus | 2 | ALA3396967 | cell-based format | Scientific Literature | |
| 17. | ALA3398859 | F | Antiviral activity against Encephalomyocarditis virus infected in HEK293 cells assessed as reduction of viral titer at 25 uM by plaque reduction assay relative to untreated control | Encephalomyocarditis virus | 2 | ALA3396967 | organism-based format | Scientific Literature | |
| 18. | ALA3398860 | F | Inhibition of host cell cap-dependent translation in Cricetinae BSR-T7 cells assessed as suppression of pSV40-LUC activity at 0.1 to 10 uM after 20 hrs | Cricetinae | 3 | ALA3396967 | cell-based format | Scientific Literature | |
| 19. | ALA3398861 | F | Inhibition of host cell cap-independent translation in Cricetinae BSR-T7 cells assessed as suppression of pT7/CITE-LUC activity at 0.1 to 10 uM after 20 hrs | Cricetinae | 2 | ALA3396967 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!